GWP42003-P
Sponsors
Yamamoto Tomoyuki, Jazz Pharmaceuticals, GW Research Ltd
Conditions
Autism Spectrum DisorderDravet SyndromeEpilepsyInfantile SpasmsLennox Gastaut SyndromeLennox-Gastaut SyndromeLennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complexRTT
Phase 2
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
CompletedNCT02564952
Start: 2016-03-11End: 2017-06-07Updated: 2022-09-28
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
CompletedNCT02607904
Start: 2016-12-15End: 2019-05-27Updated: 2022-12-20
A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
CompletedNCT02607891
Start: 2016-11-09End: 2018-10-02Updated: 2022-12-20
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
TerminatedNCT04421456
Start: 2020-08-18End: 2022-03-16Updated: 2023-06-15
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
CompletedNCT04745026
Start: 2021-05-31End: 2023-12-21Updated: 2025-03-30
Phase 3
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
CompletedNCT02224573
Start: 2015-06-11End: 2020-09-24Updated: 2022-02-03
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
CompletedNCT02224560
Start: 2015-06-08End: 2016-05-19Updated: 2022-09-28
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
CompletedNCT02224703
Start: 2015-04-13End: 2018-04-09Updated: 2022-09-28
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
CompletedNCT02544750
Start: 2016-08-31End: 2021-06-11Updated: 2022-07-14
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
CompletedNCT02544763
Start: 2016-04-06End: 2019-02-26Updated: 2022-09-28
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
CompletedNCT02953548
Start: 2017-04-24End: 2018-05-07Updated: 2022-09-02
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
CompletedNCT02954887
Start: 2017-05-12End: 2019-06-13Updated: 2022-09-02
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
TerminatedNCT03848832
Start: 2019-07-29End: 2021-01-21Updated: 2022-09-02
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
TerminatedNCT04252586
Start: 2020-02-28End: 2021-06-09Updated: 2022-08-08
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
TerminatedNCT04485104
Start: 2021-05-19End: 2025-01-28Updated: 2025-10-31
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
TerminatedNCT05288283
Start: 2022-10-31End: 2023-09-28Updated: 2025-02-03
A safety and efficacy study of GWP42003-P oral solution as adjunctive treatment for Japanese children and adults with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex
Active, not recruitingJPRN-jRCT2031220041
Start: 2022-10-31Target: 84Updated: 2025-07-18
Phase 4
Related Papers
9 more papers not shown